

Marcela Del Rio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8574811/publications.pdf>

Version: 2024-02-01

82
papers

3,314
citations

126858

33
h-index

155592

55
g-index

82
all docs

82
docs citations

82
times ranked

4003
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural Occurrence of Autoantibodies against Basement Membrane Proteins in Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2014-2019.e3.	0.3	4
2	FPR2 DNA Aptamers for Targeted Therapy of Wound Repair. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2238-2248.e8.	0.3	2
3	Immunotherapeutic effect of adenovirus encoding antimicrobial peptides in experimental pulmonary tuberculosis. <i>Journal of Leukocyte Biology</i> , 2021, 110, 951-963.	1.5	5
4	Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. <i>Molecular Therapy</i> , 2021, 29, 2008-2018.	3.7	20
5	Transcriptomic Analysis of a Diabetic Skin-Humanized Mouse Model Dissects Molecular Pathways Underlying the Delayed Wound Healing Response. <i>Genes</i> , 2021, 12, 47.	1.0	6
6	Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. <i>Frontiers in Medicine</i> , 2020, 7, 576558.	1.2	7
7	Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 280-290.	1.8	10
8	Combined adipose mesenchymal stromal cell advanced therapy resolved a recalcitrant leg ulcer in an 85-year-old patient. <i>Regenerative Medicine</i> , 2020, 15, 2053-2065.	0.8	2
9	The importance of immunity in the development of reliable animal models for psoriasis and atopic dermatitis. <i>Immunology and Cell Biology</i> , 2020, 98, 626-638.	1.0	9
10	Humanization of Tumor Stroma by Tissue Engineering as a Tool to Improve Squamous Cell Carcinoma Xenograft. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1951.	1.8	3
11	Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 183.	1.2	16
12	Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. <i>JCI Insight</i> , 2019, 4, .	2.3	56
13	Terapias avanzadas en enfermedades raras. <i>Arbor</i> , 2018, 194, 467.	0.1	1
14	CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient. <i>Molecular Therapy</i> , 2018, 26, 2592-2603.	3.7	46
15	COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa. <i>Molecular Therapy</i> , 2017, 25, 2573-2584.	3.7	81
16	Effects of photodynamic therapy on dermal fibroblasts from xeroderma pigmentosum and Gorlin-Goltz syndrome patients. <i>Oncotarget</i> , 2017, 8, 77385-77399.	0.8	22
17	Current Applications for Bioengineered Skin. , 2016, , 107-120.		1
18	Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2263-2273.	2.9	42

#	ARTICLE	IF	CITATIONS
19	Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e307.	2.3	50
20	Long-term skin regeneration in xenografts from iPSC teratoma-derived human keratinocytes. <i>Experimental Dermatology</i> , 2016, 25, 736-738.	1.4	4
21	Differential Features between Chronic Skin Inflammatory Diseases Revealed in Skin-Humanized Psoriasis and Atopic Dermatitis Mouse Models. <i>Journal of Investigative Dermatology</i> , 2016, 136, 136-145.	0.3	37
22	IKK β regulates the stratification and differentiation of the epidermis: implications for skin cancer development. <i>Oncotarget</i> , 2016, 7, 76779-76792.	0.8	13
23	Tumor initiation by skin Ha β expression. <i>Experimental Dermatology</i> , 2015, 24, 252-253.	1.4	0
24	Feeder Layer Cell Actions and Applications. <i>Tissue Engineering - Part B: Reviews</i> , 2015, 21, 345-353.	2.5	122
25	Estrategias terapéuticas innovadoras para la epidermolisis bullosa distrófica recesiva. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 376-382.	0.2	15
26	Increased Susceptibility to Skin Carcinogenesis Associated with a Spontaneous Mouse Mutation in the Palmitoyl Transferase Zdhhc13 Gene. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3133-3143.	0.3	22
27	Oxidative stress and mitochondrial dysfunction in Kindler syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 211.	1.2	20
28	Long-Term Survival of Type XVII Collagen Revertant Cells in an Animal Model of Revertant Cell Therapy. <i>Journal of Investigative Dermatology</i> , 2014, 134, 571-574.	0.3	23
29	Tissue-Engineered Oral Mucosa for Mucosal Reconstruction in a Pediatric Patient with Hemifacial Microsomia and Ankyloglossia. <i>Cleft Palate-Craniofacial Journal</i> , 2014, 51, 246-251.	0.5	15
30	Remote diffuse reflectance spectroscopy sensor for tissue engineering monitoring based on blind signal separation. <i>Biomedical Optics Express</i> , 2014, 5, 3231.	1.5	6
31	Long-Term Skin Regeneration From a Gene-Targeted Human Epidermal Stem Cell Clone. <i>Molecular Therapy</i> , 2014, 22, 1878-1880.	3.7	13
32	Aplasia cutis congenita with dystrophic epidermolysis bullosa: clinical and mutational study. <i>British Journal of Dermatology</i> , 2014, 170, 901-906.	1.4	30
33	Pigmentation and melanocyte supply to the epidermis depend on type XVII collagen. <i>Experimental Dermatology</i> , 2014, 23, 130-132.	1.4	10
34	Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies. <i>Experimental Dermatology</i> , 2014, 23, 199-201.	1.4	47
35	Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2097-2104.	0.3	40
36	Topical Enzyme-Replacement Therapy Restores Transglutaminase 1 Activity and Corrects Architecture of Transglutaminase-1-Deficient Skin Grafts. <i>American Journal of Human Genetics</i> , 2013, 93, 620-630.	2.6	53

#	ARTICLE	IF	CITATIONS
37	The regenerative potential of fibroblasts in a new diabetes-induced delayed humanised wound healing model. <i>Experimental Dermatology</i> , 2013, 22, 195-201.	1.4	34
38	Bioengineered Skin Humanized Model of Psoriasis. <i>Methods in Molecular Biology</i> , 2013, 961, 305-323.	0.4	6
39	Targeted Gene Addition in Human Epithelial Stem Cells by Zinc-finger Nuclease-mediated Homologous Recombination. <i>Molecular Therapy</i> , 2013, 21, 1695-1704.	3.7	53
40	Epidermolysis Bullosa Simplex with Mottled Pigmentation: A Family Report and Review. <i>Pediatric Dermatology</i> , 2013, 30, e125-31.	0.5	17
41	Keratinocyte cell lines derived from severe generalized recessive epidermolysis bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies <i>in vitro</i> and <i>in vivo</i> . <i>Experimental Dermatology</i> , 2013, 22, 601-603.	1.4	20
42	Long-Term Faithful Recapitulation of Transglutaminase 1-Deficient Lamellar Ichthyosis in a Skin-Humanized Mouse Model, and Insights from Proteomic Studies. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1918-1921.	0.3	27
43	Human Involucrin Promoter Mediates Repression-Resistant and Compartment-Specific LEKTI Expression. <i>Human Gene Therapy</i> , 2012, 23, 83-90.	1.4	11
44	Preclinical Corrective Gene Transfer in Xeroderma Pigmentosum Human Skin Stem Cells. <i>Molecular Therapy</i> , 2012, 20, 798-807.	3.7	44
45	A Humanized Mouse Model of HPV-Associated Pathology Driven by E7 Expression. <i>PLoS ONE</i> , 2012, 7, e41743.	1.1	23
46	Kindler syndrome: Extension of FERMT1 mutational spectrum and natural history. <i>Human Mutation</i> , 2011, 32, 1204-1212.	1.1	102
47	Ex-vivo Gene Therapy Restores LEKTI Activity and Corrects the Architecture of Netherton Syndrome-derived Skin Grafts. <i>Molecular Therapy</i> , 2011, 19, 408-416.	3.7	65
48	Applicability of bioengineered human skin: From preclinical skin humanized mouse models to clinical regenerative therapies. <i>Bioengineered Bugs</i> , 2011, 2, 203-207.	2.0	11
49	Development of Skin-Humanized Mouse Models of Pachyonychia Congenita. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1053-1060.	0.3	32
50	A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families. <i>BMC Medical Genetics</i> , 2010, 11, 139.	2.1	18
51	Revertant Mosaicism Due to a Second-Site Mutation in COL7A1 in a Patient with Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2407-2411.	0.3	51
52	In Vivo Assessment of Acute UVB Responses in Normal and Xeroderma Pigmentosum (XP-C) Skin-Humanized Mouse Models. <i>American Journal of Pathology</i> , 2010, 177, 865-872.	1.9	30
53	Development of a Bioengineered Skin-Humanized Mouse Model for Psoriasis. <i>American Journal of Pathology</i> , 2010, 177, 3112-3124.	1.9	51
54	Human embryonic stem-cell derivatives for full reconstruction of the pluristratified epidermis: a preclinical study. <i>Lancet, The</i> , 2009, 374, 1745-1753.	6.3	233

#	ARTICLE	IF	CITATIONS
55	Epidermalis ampollosa distrífica recesiva y gestaci³n. Progresos En Obstetricia Y Ginecologia, 2009, 52, 529-532.	0.0	0
56	In vitro and In vivo Wound Healing-Promoting Activities of Human Cathelicidin LL-37. Journal of Investigative Dermatology, 2008, 128, 223-236.	0.3	284
57	Assessment of Optimal Virus-Mediated Growth Factor Gene Delivery for Human Cutaneous Wound Healing Enhancement. Journal of Investigative Dermatology, 2008, 128, 1565-1575.	0.3	46
58	Correction of Laminin-5 Deficiency in Human Epidermal Stem Cells by Transcriptionally Targeted Lentiviral Vectors. Molecular Therapy, 2008, 16, 1977-1985.	3.7	60
59	Safe Selection of Genetically Manipulated Human Primary Keratinocytes with Very High Growth Potential Using CD24. Molecular Therapy, 2007, 15, 2186-2193.	3.7	25
60	Long-term Engraftment of Single Genetically Modified Human Epidermal Holoclones Enables Safety Pre-assessment of Cutaneous Gene Therapy. Molecular Therapy, 2007, 15, 1670-1676.	3.7	64
61	Modeling normal and pathological processes through skin tissue engineering. Molecular Carcinogenesis, 2007, 46, 741-745.	1.3	34
62	Sustained phenotypic reversion of junctional epidermolysis bullosa dog keratinocytes: Establishment of an immunocompetent animal model for cutaneous gene therapy. Biochemical and Biophysical Research Communications, 2006, 339, 769-778.	1.0	30
63	Clinical Results of an Autologous Engineered Skin. Cell and Tissue Banking, 2006, 7, 47-53.	0.5	93
64	1Î±,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene, 2005, 24, 6533-6544.	2.6	91
65	Targeted Overexpression of Leptin to Keratinocytes in Transgenic Mice Results in Lack of Skin Phenotype but Induction of Early Leptin Resistance. Endocrinology, 2005, 146, 4167-4176.	1.4	17
66	Construction of Skin Equivalents for Gene Therapy of Recessive Dystrophic Epidermolysis Bullosa. Human Gene Therapy, 2004, 15, 921-933.	1.4	89
67	Inhibition of Xenografted Human Melanoma Growth and Prevention of Metastasis Development by Dual Antiangiogenic/Antitumor Activities of Pigment Epithelium-Derived Factor. Cancer Research, 2004, 64, 5632-5642.	0.4	93
68	A cutaneous gene therapy approach to treat infection through keratinocyteâ€targeted overexpression of antimicrobial peptides. FASEB Journal, 2004, 18, 1931-1933.	0.2	62
69	An In Vivo Model of Wound Healing in Genetically Modified Skin-Humanized Mice. Journal of Investigative Dermatology, 2004, 123, 1182-1191.	0.3	104
70	Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation, 2004, 77, 350-355.	0.5	168
71	Acetylsalicylic Acid Inhibits Cell Proliferation by Involving Transforming Growth Factor-Î². Circulation, 2003, 107, 626-629.	1.6	49
72	A Comparison of Targeting Performance of Oncoretroviral Versus Lentiviral Vectors on Human Keratinocytes. Human Gene Therapy, 2003, 14, 1579-1585.	1.4	21

#	ARTICLE	IF	CITATIONS
73	Recent advances in gene therapy with skin cells. <i>European Review</i> , 2002, 10, 369-388.	0.4	3
74	A Preclinical Model for the Analysis of Genetically Modified Human Skin In Vivo. <i>Human Gene Therapy</i> , 2002, 13, 959-968.	1.4	91
75	Growth inhibitory activity of indapamide on vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 2001, 428, 19-27.	1.7	13
76	A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. <i>FASEB Journal</i> , 2001, 15, 1529-1538.	0.2	68
77	Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. <i>FASEB Journal</i> , 2001, 15, 2030-2032.	0.2	84
78	Effect of somatostatin on resistance and on capacitance rabbit isolated arteries. <i>European Journal of Pharmacology</i> , 2000, 388, 255-261.	1.7	3
79	Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells. <i>British Journal of Pharmacology</i> , 1997, 120, 1360-1366.	2.7	4
80	Effects of Indapamide on Atherosclerosis Development in Cholesterol-Fed Rabbits. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 25, 973-978.	0.8	14
81	Comparative study of elgodipine and nisoldipine on the contractile responses of various isolated blood vessels. <i>European Journal of Pharmacology</i> , 1995, 285, 115-122.	1.7	15
82	Effects of indapamide on contractile responses and $^{45}\text{Ca}^{2+}$ movements in various isolated blood vessels. <i>European Journal of Pharmacology</i> , 1993, 250, 133-139.	1.7	8